NOXO.F Stock Overview
A biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Noxopharm Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.045 |
52 Week High | AU$0.045 |
52 Week Low | AU$0.03 |
Beta | 0.78 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -92.50% |
5 Year Change | n/a |
Change since IPO | -76.32% |
Recent News & Updates
Recent updates
Shareholder Returns
NOXO.F | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | -2.7% | -2.6% |
1Y | n/a | -6.2% | 23.1% |
Return vs Industry: Insufficient data to determine how NOXO.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how NOXO.F performed against the US Market.
Price Volatility
NOXO.F volatility | |
---|---|
NOXO.F Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 10.7% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 17.8% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NOXO.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NOXO.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | n/a | Gisela Mautner | www.noxopharm.com |
Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia. It primarily develops Veyonda, a formulation of idronoxil for the treatment of solid tumors. The company also develops LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types.
Noxopharm Limited Fundamentals Summary
NOXO.F fundamental statistics | |
---|---|
Market cap | US$14.62m |
Earnings (TTM) | -US$7.98m |
Revenue (TTM) | US$2.55m |
5.8x
P/S Ratio-1.9x
P/E RatioIs NOXO.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NOXO.F income statement (TTM) | |
---|---|
Revenue | AU$3.88m |
Cost of Revenue | AU$6.30m |
Gross Profit | -AU$2.43m |
Other Expenses | AU$9.70m |
Earnings | -AU$12.13m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.041 |
Gross Margin | -62.60% |
Net Profit Margin | -312.86% |
Debt/Equity Ratio | 0% |
How did NOXO.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/08/12 22:53 |
End of Day Share Price | 2024/05/15 00:00 |
Earnings | 2023/12/31 |
Annual Earnings | 2023/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Noxopharm Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|